Effects of HCV genotypes and HLA-DRB alleles on the response of chronic hepatitis C patients to interferon alpha and libavilin.
- Author:
Jian JIAO
1
;
Jiang-bin WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Alleles; Antiviral Agents; therapeutic use; Drug Therapy, Combination; Female; Genotype; HLA-DR Antigens; genetics; HLA-DRB1 Chains; Hepacivirus; classification; genetics; Hepatitis C, Chronic; drug therapy; immunology; virology; Humans; Interferon-alpha; therapeutic use; Male; Middle Aged; Ribavirin; therapeutic use
- From: Chinese Journal of Hepatology 2003;11(10):620-622
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo study the effects of HCV genotypes and HLA-DRB alleles on the response of chronic hepatitis C patients to interferon alpha and libavilin.
METHODSGenotypes of HCV in 113 patients with HCV infection treated with interferon alpha and libavilin were investigated. Gene chips were used to analyze the frequency of HLA-DRB alleles in 25 patients of them. The response to interferon alpha and libavilin therapy were discussed.
RESULTSThe response rates in the four HCV types were different, HCV-IV/2b the highest (57.78%), HCV-I/1a and -III/2a lower (46.15% and 47.62%), and HCV-II/1b the lowest (11.76%). The response rate to IFN and libavilin therapy in patients with DRB1*07 positive was higher, while in patients with DRB1*04 positive was lower. Sex, HCV genotypes and HLA-DRB alleles were all related to the response. Female, patients with HCV-IV/2b and HLA-DRB1*07 presented almost complete response, but male, patients with HCV-II/1b and HLA-DRB1*04 usually appeared non-response. DRB1*07 allele and HCV-IV/2b were the closest factors related to the response.
CONCLUSIONSNot only virus but also host playes an important role in the curative effect of anti-virus therapy. It is necessary to view from the angle of host, adjusting the host's immune status to accelerate the clearance of HCV.
